相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1962
已完成
3
100.0%
暂无批准数据
- Medley Therapeutics completed dosing of the first three patients with YAP101, marking the first clinical investigation of a genetic medicine designed to induce endogenous cardiac regeneration. - The Phase 1 SALVADOR-HF trial's independent Safety Review Team recommended dose escalation after favorable safety findings in patients with advanced ischemic heart failure. - YAP101 uses an AAV vector to deliver shRNAs that transiently suppress Hippo signaling and activate YAP, enabling self-limiting myocardial regeneration through the heart's own repair mechanisms. - The trial represents a potential breakthrough for treating heart failure, a condition affecting tens of millions globally with limited regenerative treatment options.
• The FDA has authorized Phase 2 clinical trials for the BiVACOR mechanical heart, allowing 15 additional patients to receive the device and recover at home while awaiting donor hearts. • The innovative BiVACOR device features a single moving part - a magnetically suspended spinning disc - potentially offering a more durable and permanent alternative to traditional heart transplants. • The first human recipient, Batson Avie, experienced immediate improvement after implantation at Texas Heart Institute, demonstrating the device's promising potential for treating advanced heart failure.
- A pooled analysis of the NUDGE-FLU trials shows email reminders increase flu vaccination rates among patients with a history of acute myocardial infarction. - Targeted messaging emphasizing cardiovascular benefits of flu shots was particularly effective for vaccine-hesitant and younger post-MI patients. - The study highlights the potential of simple, scalable interventions to improve vaccination rates in high-risk cardiovascular patients. - Experts caution generalizing results to the US due to healthcare system differences and vaccine hesitancy challenges.
